首页 | 本学科首页   官方微博 | 高级检索  
     

肝衰竭合并巨细胞病毒再激活患者的临床特征及预后分析
引用本文:杨学芳,杨清銮,陈宇明,刘爱平,郑建铭,万红,邵凌云,张文宏. 肝衰竭合并巨细胞病毒再激活患者的临床特征及预后分析[J]. 中华传染病杂志, 2021, 0(2): 80-85
作者姓名:杨学芳  杨清銮  陈宇明  刘爱平  郑建铭  万红  邵凌云  张文宏
作者单位:兰州市第二人民医院感染科;复旦大学附属华山医院感染科;复旦大学附属华山医院检验科
基金项目:国家自然科学基金(81371821、81670560);上海市自然科学基金(19ZR1407800)。
摘    要:目的:探讨肝衰竭患者巨细胞病毒(cytomegalovirus,CMV)再激活的临床特征及预后转归。方法:纳入2016年1月至2019年6月于上海复旦大学附属华山医院感染科诊断为肝衰竭,并进行血清CMV DNA检测的住院患者共75例,根据CMV DNA检测结果分成CMV DNA阳性组和CMV DNA阴性组,比较两组的肝...

关 键 词:肝功能衰竭  巨细胞病毒  再激活

Clinical characteristics and prognosis analysis of cytomegalovirus reactivation in patients with liver failure
Yang Xuefang,Yang Qingluan,Chen Yuming,Liu Aiping,Zheng Jianming,Wan Hong,Shao Lingyun,Zhang Wenhong. Clinical characteristics and prognosis analysis of cytomegalovirus reactivation in patients with liver failure[J]. Chinese Journal of Infectious Diseases, 2021, 0(2): 80-85
Authors:Yang Xuefang  Yang Qingluan  Chen Yuming  Liu Aiping  Zheng Jianming  Wan Hong  Shao Lingyun  Zhang Wenhong
Affiliation:(Department of Infectious Diseases,The Second People′s Hospital of Lanzhou City,Lanzhou 730040,China;Department of Infectious Diseases,Huashan Hospital,Fudan University,Shanghai 200040,China;Department of Laboratory,Huashan Hospital,Fudan University,Shanghai 200040,China)
Abstract:Objective To investigate the clinical characteristics and prognosis of cytomegalovirus(CMV)reactivation in patients with liver failure.Methods A total of 75 patients diagnosed with liver failure and tested for serum CMV DNA between January 2016 and June 2019 in Huashan Hospital,Fudan University were retrospectively analyzed.According to the CMV DNA test results,the patients were divided into CMV DNA positive group and CMV DNA negative group.The classification of liver failure,the use of glucocorticoids,the proportions of T lymphocyte subsets of the two groups were compared and the prognosis was evaluated.Mann-Whitney U test and chi-square test were used to analyze the data.Results Of the 75 patients with liver failure,17 were CMV DNA positive and 58 were CMV DNA negative.Among the 17 CMV DNA positive patients,nine were acute(subacute)liver failure,and 13 were treated with glucocorticoids,which were all significantly higher than those in the CMV negative group(20.7%(12/58)and 20.7%(12/58),respectively).The differences were both statistically significant(χ2=6.70 and 18.40,respectively,both P<0.05).The proportions of CD3+T lymphocytes and CD8+T lymphocytes in the CMV DNA positive group were both higher than those in the CMV DNA negative group,and the proportions of CD4+T lymphocytes,the ratio of CD4+/CD8+T lymphocytes and the proportion of B lymphocytes were all lower than those in the CMV DNA negative group.The differences were all statistically significant(U=274.50,165.50,273.00,185.00 and 189.00,respectively,all P<0.05).Acute(subacute)liver failure(odds ratio(OR)=4.3,95%confidence interval(CI)1.3-12.6)and glucocorticoid use(OR=12.5,95%CI 3.4-38.3)were risk factors for CMV reactivation in patients with liver failure.The disease improvement rate in the CMV DNA negative group was 56.9%(33/58),and five out of 17 patients improved in the CMV DNA positive group,with a statistically significant difference(χ2=1.99,P=0.04).Conclusions The use of glucocorticoids increases the risk of CMV reactivation in patients with liver failure,and CMV reactivation in patients with liver failure presents immune disorders which seriously affect their prognosis.Therefore,it is important to pay attention to CMV DNA monitoring in patients with liver failure using glucocorticoids.
Keywords:Liver failure  Cytomegalovirus  Reactivation
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号